• Home
  • News

Sichenzia Ross Ference LLP Represents Laidlaw & Company (UK) Ltd. in $5.75 Million Public Offering and Nasdaq Uplisting of Silo Pharma, Inc.

silopharma logo

Press Release – New York, NY – October 3, 2020 – Sichenzia Ross Ference LLP announced today that it represented Laidlaw & Company (UK) Ltd. in the $5.75 million initial public offering and Nasdaq uplisting of Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research.  1,150,000 shares of common stock, which included the full exercise of the underwriters’ over-allotment option, were sold to the public at a price of $5.00 per share.  Silo Pharma’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “SILO” on September 27, 2022.

Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for the offering.  The Benchmark Company, LLC acted as the co-manager for the offering. 

The Sichenzia Ross Ference LLP team was led by partners Michael Ference and Barrett DiPaolo and associates Matt Siracusa and Kayla Scoccola.

Sichenzia Ross Ference LLP
Latest posts by Sichenzia Ross Ference LLP (see all)